Torsdag 26 December | 13:22:22 Europe / Stockholm

Prenumeration

2024-11-01 13:22:00

Redeye comments on BioInvent's Q3 report, which presented new data for the subcutaneous version of BI-1206 in combination with rituximab in lymphoma.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/